Wayne MacFadden: AstraZeneca, Seroquel, patents and BOLDER

Treatment of psychoses with dibenzothiazepine antipsychotic

USPTO Application #: 20050171088
Title: Treatment of psychoses with dibenzothiazepine antipsychotic (Seroquel)

Abstract: The present invention provides methods for treating depression symptoms associated with bipolar disorder. (end of abstract)

Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property - Wilmington, DE, US

Inventors: Brian Ault, Gilbert Block, Martin Brecher, Wayne MacFadden, Robin McCoy, Margaret Minkwitz, Jamie Mullen, Ellis Wilson

USPTO Applicaton #: 20050171088 - Class: 514211130 (USPTO)

Seroquel/AstraZeneca/dibenzothiazepine derivatives

SEROQUEL® (quetiapine fumarate) is a psychotropic agent belonging to a chemical class, the dibenzothiazepine derivatives.

Seroquel Drug Trial

A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine(Seroquel) in the Treatment of Bipolar I or II Depression -2005

Joseph R. Calabrese, M.D., Paul E. Keck Jr., M.D., Wayne Macfadden, M.D., Margaret Minkwitz, Ph.D., Terence A. Ketter, M.D., Richard H. Weisler, M.D., Andrew J. Cutler, M.D., Robin McCoy, R.N., Ellis Wilson, M.S., and Jamie Mullen, M.D.
The BOLDER Study Group
~
AstraZeneca funds Seroquel for poster presentation-2005-Wayne MacFadden

42. DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUETIAPINE IN BIPOLAR DEPRESSION - Wayne MacFadden, MD; Joseph R. Calabrese, MD[1], Wayne MacFadden, MD[2], Robin McCoy, RN[2], Margaret Minkwitz, PhD[2], Ellis Wilson[2], Jamie Mullen, MD[2] 1. University Hospitals of Cleveland. Cleveland, Ohio USA. 2. AstraZeneca. Wilmington, Delaware USA. Research supported by a grant from AstraZeneca.